S17 Ep15: FES-PET/CT Reshapes Treatment Planning in Lobular Breast Cancer and Beyond: With Megan Kruse, MD

S17 Ep15: FES-PET/CT Reshapes Treatment Planning in Lobular Breast Cancer and Beyond: With Megan Kruse, MD

From OncLive® On Air by OncLive® On Air

May 1, 2026 · 16 min · Season 17 · Episode 15

About this episode

Dr. Kruse discusses the impact of FES-PET/CT on treatment planning for lobular breast cancer.

Dr Kruse discussed the evolving role of FES-PET/CT in breast cancer, particularly invasive lobular carcinoma. She explained that FES-PET/CT uses a radiotracer to map estrogen receptor–positive cancer sites, offering advantages over traditional imaging. FIndings from a study presented at the 2025 San Antonio Breast Cancer Symposium showed that many patients experienced treatment changes based on FES-PET/CT results. The National Comprehensive Cancer Network guidelines also now recommend FES-PET/CT for use in lobular breast cancer, enhancing its clinical utility. Dr Kruse concluded by emphasizing that future research is needed to explore its use in early-stage breast cancer and for monitoring endocrine therapy response.

People in this episode

Guest: Megan Kruse, MD

Topics covered

  • breast cancer
  • FES-PET/CT
  • treatment planning
  • lobular carcinoma
  • clinical guidelines

Keywords

  • FES-PET/CT
  • lobular breast cancer
  • treatment changes
  • estrogen receptor
  • clinical utility

Mentioned in this episode

Organizations: National Comprehensive Cancer Network

Books & works: FES-PET/CT, lobular breast cancer, endocrine therapy

More episodes of OncLive® On Air

Explore listener stats, chart rankings, contacts and more on the OncLive® On Air podcast page.